Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
Human glandular kallikrein (KLK2) is a highly prostate-specific serine protease, which is mainly excreted into the seminal fluid, but part of which is also secreted into circulation from prostatic tumors. Since the expression level of KLK2 is elevated in aggressive tumors and it has been suggested to mediate the metastasis of prostate cancer, inhibition of the proteolytic activity of KLK2 is of potential therapeutic value. We have previously identified several KLK2-specific linear peptides by phage display technology. Two of its synthetic analogs, A R R P A P A P G (KLK2a) and G A A R F K V W W A A G (KLK2b), show specific inhibition of KLK2 but their sensitivity to proteolysis in vivo may restrict their potential use as therapeutic agents. In order to improve the stability of the linear peptides for in vivo use, we have prepared cyclic analogs and compared their biological activity and their structural stability. A series of cyclic variants with cysteine bridges were synthesized. Cyclization inactivated one peptide (KLK2a) and its derivatives, while the other peptide (KLK2b) and its derivatives remained active. Furthermore, backbone cyclization of KLK2b improved significantly the resistance against proteolysis by trypsin and human plasma. Nuclear magnetic resonance studies showed that cyclization of the KLK2b peptides does not make the structures more rigid. In conclusion, we have shown that backbone cyclization of KLK2 inhibitory peptides can be used to increase stability without losing biological activity. This should render the peptides more useful for in vivo applications, such as tumor imaging and prostate cancer targeting.
Pakkala
Miikka
M
Department of Chemistry, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, and Department of Clinical Chemistry, Helsinki University Central Hospital, Finland.
Hekim
Can
C
Soininen
Pasi
P
Leinonen
Jari
J
Koistinen
Hannu
H
Weisell
Janne
J
Stenman
Ulf-Håkan
UH
Vepsäläinen
Jouko
J
Närvänen
Ale
A
D000818:Animals; D018360:Crystallography, X-Ray; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D011485:Protein Binding; D020836:Protein Structure, Quaternary; D015842:Serine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D020840:Tissue Kallikreins / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism
D009842:Oligopeptides; D015842:Serine Proteinase Inhibitors; D020840:Tissue Kallikreins